BMT backs Oncgnostics series-A

Existing investors High-Tech Gründerfonds (HTGF) and the Foundation for Technology, Innovation and Research in Thüringen (STIFT) have also participated in the round and increased their stakes.

The Sparkasse Jena-Saale-Holzland bank and business angel Anastasia Zepik are new investors and have committed to the round, which amounted to more than €1m.

The company plans to use the funding to obtain a CE mark for its cervical cancer diagnostics test GynTect, which will enable it to bring the test to market.

Previous financing
In April 2012, HTGF invested €500,000 in Oncgnostics. STIFT provided an additional €100,000. The funding enabled it to implement a quality management system and to develop its first test, GynTect.

Company
Oncgnostics span out of the womens hospital in Jena's university in February 2012. The company develops molecular diagnostic tests for use in cancer screening, therapy decision and follow-up care. Its GynTect product detects cervical pre-cancerous lesions and cancer. The company has 10 Jena-based employees.

People
Udo Werner is CEO of BMT Beteiligungsmanagement Thüringen. Alfred Hansel is CEO at Oncgnostics.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Germany
• High-Tech Gründerfonds